University of Kentucky spinoff licensed to develop Alzheimer's treatment
Thursday, September 22, 2011 - 11:04
in Health & Medicine
CoPlex Therapeutics has signed an exclusive global license agreement with Hawthorn Pharmaceuticals to develop and commercialize hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.